SABS FY2024 EPS Reduced by Brookline Capital Management

SAB Biotherapeutics, Inc. (NASDAQ:SABS) – Analysts at Brookline Capital Management dropped their FY2024 earnings per share (EPS) estimates for SAB Biotherapeutics in a report issued on Thursday, November 7th. Brookline Capital Management analyst K. Raja now anticipates that the company will post earnings of ($3.58) per share for the year, down from their previous forecast of ($3.48). The consensus estimate for SAB Biotherapeutics’ current full-year earnings is ($3.64) per share. Brookline Capital Management also issued estimates for SAB Biotherapeutics’ Q4 2024 earnings at ($1.12) EPS, FY2025 earnings at ($0.97) EPS, FY2026 earnings at ($0.99) EPS, FY2027 earnings at ($1.02) EPS and FY2028 earnings at ($0.95) EPS.

SAB Biotherapeutics (NASDAQ:SABS) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($1.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.05). SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.37%.

A number of other brokerages also recently weighed in on SABS. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price objective on shares of SAB Biotherapeutics in a research report on Monday, August 12th. Craig Hallum assumed coverage on SAB Biotherapeutics in a report on Wednesday, October 9th. They set a “buy” rating and a $11.00 target price for the company. Oppenheimer reissued an “outperform” rating and issued a $12.00 price target on shares of SAB Biotherapeutics in a report on Thursday, September 12th. Finally, Chardan Capital restated a “buy” rating and set a $25.00 price objective on shares of SAB Biotherapeutics in a research note on Thursday, November 7th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, SAB Biotherapeutics presently has an average rating of “Buy” and a consensus price target of $12.40.

SAB Biotherapeutics Stock Performance

SABS stock opened at $3.42 on Monday. SAB Biotherapeutics has a 1-year low of $2.16 and a 1-year high of $9.72. The firm has a fifty day moving average price of $2.91 and a two-hundred day moving average price of $2.99. The company has a current ratio of 3.69, a quick ratio of 5.24 and a debt-to-equity ratio of 0.09.

Hedge Funds Weigh In On SAB Biotherapeutics

An institutional investor recently bought a new position in SAB Biotherapeutics stock. First PREMIER Bank purchased a new position in shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 19,386 shares of the company’s stock, valued at approximately $60,000. First PREMIER Bank owned 0.21% of SAB Biotherapeutics as of its most recent filing with the Securities and Exchange Commission. 7.82% of the stock is owned by institutional investors and hedge funds.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.